SCHEMBL6769676

SCHEMBL6769676

Cn1ccc2c1C=CCN(CCCN1CCN(c3ncccn3)CC1)C2=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 7/20 0.55
DRD2 P14416 8/20 0.51
DRD1 P21728 2/20 0.51
HTR1A P08908 8/20 0.50
HTR2A P28223 5/20 0.46
DRD4 P21917 2/20 0.45
HTR7 P34969 4/20 0.44
HTR6 P50406 4/20 0.44
ABCB11 O95342 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2D6 P10635 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
ADRA1D P25100 1/20 0.44
CYP2C19 P33261 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769681 0.85 DRD3 (0.53) DRD3DRD2HTR1ADRD4HTR7
SCHEMBL6770011 0.81 DRD2 (0.53) DRD3DRD2HTR1AHTR2ADRD4
SCHEMBL6773794 0.81 KDM4E (0.47) DRD3DRD2HTR1ADRD4
SCHEMBL6773781 0.81 DRD3 (0.42) DRD3DRD2HTR1AHTR7
SCHEMBL6774608 0.81 KCNH2 (0.53) DRD3DRD2HTR1ADRD4
SCHEMBL6773509 0.80 DRD3 (0.44) DRD3DRD2DRD1HTR1AHTR2A
SCHEMBL6780873 0.80 DRD3 (0.61) DRD3DRD2DRD1HTR1ADRD4
SCHEMBL6773870 0.80 DRD3 (0.57) DRD3DRD2DRD1HTR1AHTR2A
SCHEMBL6780529 0.79 HTR1A (0.46) DRD3DRD2HTR1ADRD4HTR7
SCHEMBL6774523 0.78 DRD3 (0.69) DRD3DRD2DRD1HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713634-B2 SEROTONIN RECEPTOR ANTAGONIST DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-03-30 US disclosed
US-20030166926-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2003-09-04 US disclosed
US-6489473-B2 FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION SUNTORY LIMITED (JP) 2002-12-03 US disclosed
US-20020072515-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2002-06-13 US disclosed
EP-0807632-B1 PYRROLOAZEPINE DERIVATIVES SUNTORY LTD (JP) 2002-04-17 EP disclosed
US-6258805-B1 TREATMENT OF BRAIN DISORDERS AND HYPERTENSION SUNTORY LIMITED (JP) 2001-07-10 US disclosed
EP-0807632-A1 PYRROLOAZEPINE DERIVATIVES SUNTORY LIMITED (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072515-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C DRD3 165/4885DRD2 34/4885DRD1 141/4885
US-20030166926-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C DRD3 173/4885DRD2 34/4885DRD1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.